Ellen Sigal
Showing 1–2 of 2 transcripts.
- Milken Institute1h 3m
In Service of a Healthier Tomorrow | Global Conference 2025
Esther Krofah, Gregory Case, Judy Faulkner, Robert Ford, Pablo Legorreta, Ellen Sigal, Greg Case
Leading industry figures including Epic's Judy Faulkner and Aon's Greg Case outline a strategic roadmap for the US healthcare ecosystem to reach 2035, aiming to resolve systemic tensions between biomedical innovation and workforce deficits through widespread AI automation and GLP-1 cost management. The panel identifies critical risks such as proposed 40% cuts to NIH funding, FDA staffing reductions, and regulatory bottlenecks that threaten to undermine US leadership in global life sciences despite breakthroughs like xenotransplantation. Concluding that hope is not a strategy, the consensus calls for immediate cross-sector collaboration to align incentives, secure foundational research funding, and modernize infrastructure to prevent China from seizing global health dominance.
- Milken Institute1h 2m
Lessons Learned from COVID-19: Are There Silver Linings for Biomedical Innovation?
Esther Krofah, Francis Collins, Richard Moscicki, Ellen Sigal, Janet Woodcock
Hosted by Faster Cures, a webinar convened NIH officials and industry leaders to analyze the COVID-19 pandemic's acceleration of biomedical innovation, highlighting achievements such as the ACTIV partnership's master protocols and the RADx initiative's diagnostic scaling. The discussion detailed how the crisis forced a shift toward competitive collaboration, decentralized trials, and the successful achievement of diverse vaccine trial enrollment, while simultaneously exposing critical infrastructure gaps in clinical trial execution and real-world data integration. Panelists concluded with a consensus that emergency-driven reforms must be institutionalized through permanent policy changes and public-private partnerships to sustain preparedness for future health threats.